Breaking News, Collaborations & Alliances

EVOQ Therapeutics and Sanofi Enter Collaboration and License Agreement

EVOQ and Sanofi will jointly conduct research activities, with Sanofi assuming responsibility for global development and commercialization.

Author Image

By: Charlie Sternberg

Associate Editor

EVOQ Therapeutics Inc., a biotechnology company developing therapies for autoimmune diseases, has entered into a collaboration and license agreement with Sanofi, a global biopharmaceutical company focused on R&D and artificial intelligence-driven innovation. The partnership centers on EVOQ’s proprietary NanoDisc technology, which is designed to restore immune tolerance—a key mechanism that fails in autoimmune diseases such as celiac disease, type 1 diabetes, MOG antibody disease, rheumato...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters